A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

Inclusion Criteria: * Histologically documented locally unresectable or metastatic carcinoid neuroendocrine tumor * Measurable disease, according to RECIST, with at least one lesion that is unidimensionally measurable by conventional techniques to be greater than or equal to 2 cm in diameter, or by spiral CT to be greater than or equal to 1 cm in diameter * 18 years or older Laboratory data to include (next 7 bullet points): * Aspartate aminotransferase(AST)and alanine aminotransferase (ALT)less than 2.5 times the upper limit of normal (less than 5 times upper limit of normal if liver metastasis present) * Total bilirubin less than or equal to 2 mg/dL * Serum creatinine less than or equal to 1.5 mg/dL * Total white blood cell count greater than 3,500/mm3 * Absolute neutrophil count greater than or equal to 1,500/mm3 * International normalized ratio less then or equal to 1.5 * Platelets greater than or equal to 100,000/mm3 * Agree to use effective contraceptive methods * Have an ECOG performance status of less than 2 * Life expectancy of greater than 12 weeks * Ability to understand the requirements of the study, have provided written consent, and agree to abibe by the study restrictions Exclusion Criteria: * Pregnant or nursing, or refusal to use appropriate birth control * An active infection * Have a history of myocardial infarction or angina pectoris/angina equivalent in the last 12 months (the patient may be on antianginal medications if the symptoms can be fully controlled), or have uncontrolled congestive heart failure * Have apparent central nervous system metastasis or carcinomatous meningitis * Have had any active cancer in addition to the carcinoid tumor within the last 5 years, with the exception of superficial skin cancer * Be receiving concurrent treatment with therapeutic doses of any anticoagulant including all forms of heparin and Coumadin * Have current or a history of severe bleeding * Uncontrolled / severe hypertension * Previous history of nephrotic syndrome * Urine protein: creatinine ratio greater than or equal to 1.0 at screening * Have received radiotherapy or chemotherapy within the previous 4 weeks * Participated in any clinical trial involving conventional or investigational drugs or devices within the previous 4 weeks * Have had major surgery within 4 weeks or plan to undergo elective surgery during treatment * Additional uncontrolled serious medical condition or psychiatric illness * Have any condition that is likely to interfere with regular follow-up